Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Historically, most people started HIV treatment with two drugs from the NRTI class combined with either one NNRTI, one protease inhibitor or one integrase inhibitor – hence, ‘triple therapy’.

"This is the first phase III trial to demonstrate that a two-drug regimen without an integrase inhibitor is noninferior to BIC/FTC/TAF." In the second trial, 1.4% of those switching to islatravir ...

investigational third-generation integrase inhibitor (INSTI), demonstrates strong antiviral activity and positive safety results across multiple dose levels in people with HIV-1, supporting ...

today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased the risk of weight gain and cardiometabolic complications over the next five ...